Details:
Under the agreement, Evotec Biologics will develop drug product prototypes of new monoclonal antibodies (mAbs) using AI-driven de novo antibody design through the execution of Phase I first-in human clinical trials.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $74.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 05, 2023
Details:
The funding will support the discovery and development of RNA-targeting small molecules by leveraging its rSM platform for potential first-in-class therapeutics against Henipaviruses.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Open Philanthropy
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2023
Details:
The funding will support TB drug discovery, and will allow the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Funding March 24, 2023
Details:
Evotec Biologics will use its proprietary software toolset Abacus™ to perform an in silico analysis of several lead candidate sequences of potent anti-SARS-CoV-2 mAbs provided to the foundation by several leading academic medical centres around the world.
Lead Product(s): Anti-SARS-CoV-2 antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 19, 2020
Details:
Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Sun Yat-sen University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
Details:
Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.
Lead Product(s): NI007
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Neurimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2020